Cetuximab: clinical results in colorectal cancer.
In recent years, the introduction of targeted therapies into clinical practice seems to offer incremental benefits in the treatment of metastatic colorectal cancer (mCRC), mainly when they are employed in combination with optimal chemotherapy and/or radiotherapy. In this paper, we focus on Cetuximab and its role in the treatment of mCRC.
Maiello
E
E
Medical Oncology Unit, Istituto di ricovero e cura a carattere scientifico (IRCCS) Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia. e.maiello@operapadrepio.it
Giuliani
F
F
Gebbia
V
V
Piano
A
A
Agueli
R
R
Colucci
G
G
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068818:Cetuximab; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab